ITGAV and thyroid gland carcinoma: The TIMER data revealed that ITGAV expression was significantly elevated in various cancer tissues, including cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD) and thyroid carcinoma (THCA) (Fig. 1A).